{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:32:46Z","timestamp":1770341566227,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11845-021-02897-5","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:04:41Z","timestamp":1643328281000},"page":"2511-2515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy: real-world data"],"prefix":"10.1007","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-6051","authenticated-orcid":false,"given":"Hikmat","family":"Abdel-Razeq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ula","family":"Al-Rasheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Mashhadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashid","family":"Abdel-Razeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shereen Abu","family":"Jaradeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razan","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayan","family":"Bater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrouq","family":"Tbayshat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"issue":"3","key":"2897_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2897_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2015","unstructured":"Torre LA, Siegel R, Ward E, Jemal A (2015) Global cancer incidence and mortality rates and trends\u2013an update. Cancer Epidemiol Biomark Prev 25(1):16\u201327. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0578","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"17","key":"2897_CR3","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa050518","volume":"353","author":"DA Berry","year":"2005","unstructured":"Berry DA, Cronin KA, Plevritis SK et al (2005) Cancer intervention and surveillance modeling network (CISNET) collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784\u20131792. https:\/\/doi.org\/10.1056\/NEJMoa050518","journal-title":"N Engl J Med"},{"key":"2897_CR4","doi-asserted-by":"publisher","unstructured":"Howlader N, Altekruse S, Li C et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI: J Natl Cancer Inst 106(5):dju055. https:\/\/doi.org\/10.1093\/jnci\/dju055","DOI":"10.1093\/jnci\/dju055"},{"key":"2897_CR5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"M Baum","year":"2003","unstructured":"Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802\u20131810. https:\/\/doi.org\/10.1002\/cncr.11745","journal-title":"Cancer"},{"key":"2897_CR6","doi-asserted-by":"publisher","unstructured":"Breast International Group (BIG) 1\u201398 Collaborative Group, Th\u00fcrlimann B, Keshaviah A et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med\u00a0353:2747\u20132757. https:\/\/doi.org\/10.1056\/NEJMoa052258","DOI":"10.1056\/NEJMoa052258"},{"issue":"22","key":"2897_CR7","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"E Perez","year":"2006","unstructured":"Perez E, Josse R, Pritchard K et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 24(22):3629\u20133635. https:\/\/doi.org\/10.1200\/JCO.2005.05.4882","journal-title":"J Clin Oncol"},{"issue":"3","key":"2897_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4103\/0973-1482.87006","volume":"7","author":"H Abdel-Razeq","year":"2011","unstructured":"Abdel-Razeq H, Awidi A (2011) Bone health in breast cancer survivors. J Cancer Res Ther 7(3):256\u2013263. https:\/\/doi.org\/10.4103\/0973-1482.87006","journal-title":"J Cancer Res Ther"},{"issue":"7","key":"2897_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams J, Coleman R et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26(7):1051\u20131057. https:\/\/doi.org\/10.1200\/JCO.2007.11.0726","journal-title":"J Clin Oncol"},{"issue":"10","key":"2897_CR10","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur S, LeBoff M et al (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359\u20132381. https:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"2897_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2018.06.028","volume":"101","author":"B Bouvard","year":"2018","unstructured":"Bouvard B, Chatelais J, Souli\u00e9 P et al (2018) Osteoporosis treatment and 10 years\u2019 oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors. Eur J Cancer 101:87\u201394. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.028","journal-title":"Eur J Cancer"},{"key":"2897_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115516","volume":"139","author":"B Langdahl","year":"2020","unstructured":"Langdahl B (2020) Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches. Bone 139:115516. https:\/\/doi.org\/10.1016\/j.bone.2020.115516","journal-title":"Bone"},{"issue":"5","key":"2897_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/cncr.23259","volume":"112","author":"N Bundred","year":"2008","unstructured":"Bundred N, Campbell I, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. Cancer 112(5):1001\u20131010. https:\/\/doi.org\/10.1002\/cncr.23259","journal-title":"Cancer"},{"issue":"2","key":"2897_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24(2):398\u2013405. https:\/\/doi.org\/10.1093\/annonc\/mds277","journal-title":"Ann Oncol"},{"issue":"2","key":"2897_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"A Brufsky","year":"2009","unstructured":"Brufsky A, Bosserman L, Caradonna R et al (2009) Zoledronic acid effectively prevents aromatase inhibitor\u2013associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-fast study 36-month follow-up results. Clin Breast Cancer 9(2):77\u201385. https:\/\/doi.org\/10.3816\/CBC.2009.n.015","journal-title":"Clin Breast Cancer"},{"issue":"31","key":"2897_CR16","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C et al (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37(31):2916\u20132946. https:\/\/doi.org\/10.1200\/JCO.19.01696","journal-title":"J Clin Oncol"},{"issue":"4","key":"2897_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa022464","volume":"349","author":"HG Ahlborg","year":"2003","unstructured":"Ahlborg HG, Johnell O, Turner CH et al (2003) Bone loss and bone size after menopause. N Engl J Med 349(4):327\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa022464","journal-title":"N Engl J Med"},{"issue":"1","key":"2897_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","volume":"34","author":"SC Schuit","year":"2004","unstructured":"Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34(1):195\u2013202. https:\/\/doi.org\/10.1016\/j.bone.2003.10.001","journal-title":"Bone"},{"issue":"5","key":"2897_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1503\/cmaj.081720","volume":"181","author":"G Ioannidis","year":"2009","unstructured":"Ioannidis G, Papaioannou A, Hopman WM et al (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 181(5):265\u2013271. https:\/\/doi.org\/10.1503\/cmaj.081720","journal-title":"CMAJ"},{"issue":"3","key":"2897_CR20","doi-asserted-by":"publisher","first-page":"M101","DOI":"10.1093\/geronj\/45.3.m101","volume":"45","author":"J Magaziner","year":"1990","unstructured":"Magaziner J, Simonsick E, Kashner T et al (1990) Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 45(3):M101\u2013M107. https:\/\/doi.org\/10.1093\/geronj\/45.3.m101","journal-title":"J Gerontol"},{"key":"2897_CR21","unstructured":"US Department of Health and Human Services (2002) Bone Health and osteoporosis: a report of the surgeon general. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General 1Y55. Available at: https:\/\/www.bones.nih.gov\/health-info\/bone\/SGR\/surgeon-generals-report. Accessed on 01 Apr 2021"},{"issue":"16","key":"2897_CR22","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.3390\/ijms21165625","volume":"21","author":"S Tenti","year":"2020","unstructured":"Tenti S, Correale P, Cheleschi S et al (2020) Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects. Int J Mol Sci 21(16):5625. https:\/\/doi.org\/10.3390\/ijms21165625","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2897_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-019-05289-7","volume":"177","author":"M Pineda-Moncus\u00ed","year":"2019","unstructured":"Pineda-Moncus\u00ed M, Servitja S, Tusquets I et al (2019) Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study. Breast Cancer Res Treat 177(1):53\u201360. https:\/\/doi.org\/10.1007\/s10549-019-05289-7","journal-title":"Breast Cancer Res Treat"},{"key":"2897_CR24","unstructured":"NCCN clinical practice guidelines in oncology: Breast Cancer, version 3.2021. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 02 Apr\u00a02021"},{"issue":"1","key":"2897_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.hemonc.2020.08.005","volume":"14","author":"IA Voutsadakis","year":"2021","unstructured":"Voutsadakis IA (2021) Vitamin D baseline levels at diagnosis of breast cancer: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 14(1):16\u201326. https:\/\/doi.org\/10.1016\/j.hemonc.2020.08.005","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-021-02897-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-021-02897-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-021-02897-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T08:16:45Z","timestamp":1668673005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-021-02897-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1007\/s11845-021-02897-5","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by King Hussein Cancer Center IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent was waived by King Hussein Cancer Center IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}